Steven M. Corsello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven M. Corsello has a total of 475 co-authors. Here are the top co-authors by number of shared publications:
- Marios Giannakis
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
39 shared publications - Kimmie Ng
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
37 shared publications - Lauren K. Brais
Dana-Farber Cancer Institute, Boston, MA
37 shared publications - Matthew Meyerson
Broad Institute of MIT and Harvard, Cambridge, USA
36 shared publications - Andrew J. Aguirre
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
34 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
34 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
A BromoTag-Based Toolkit for Rapid Modulation of Chemically Induced Proximity
Mammalian cells control a wide range of essential processes via protein–protein interactions (PPIs), including signal transduction, gene expression, cell cycle regulation, and metabolism. Pathologic alterations in PPIs have been linked to many human diseases. Thus, the ability to rapidly and selectively induce PPIs in cultured cells is crucial for many fields of biological research. One proven approach is the use of synthetic bivalent chemical ligands to selectively recruit protein domains with engineered mutations (i.e., "bump-and-hole"). Developing new PPI chemical inducers with unique protein domains enables multiplexing and potentially expands the breadth of recruitable proteins. Herein, we describe the design and characterization of a BromoTag- and dTAG-based toolkit to induce protein homo- and heterodimerization. Using a NanoBiT split-luciferase assay, we characterized a library of BromoTag-based homo- (BromoTag/BromoTag) and heterobivalent (BromoTag/dTAG) compounds for their ability to induce neo-PPIs. Compounds were evaluated for activity across multiple cellular applications, including caspase-9 and c-Kit tyrosine kinase activation, with comparable activity to other dimerizer systems. This BromoTag-based protein dimerization toolkit provides a useful alternative to current controlled dimerization systems that will enable robust prototyping of chemically induced proximity.
- 29 October 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Open AccessA BromoTag-Based Toolkit for Rapid Modulation of Chemically Induced Proximity
Mammalian cells control a wide range of essential processes via protein–protein interactions (PPIs), including signal transduction, gene expression, cell cycle regulation, and metabolism. Pathologic alterations in PPIs have been linked to many human diseases. Thus, the ability to rapidly and selectively induce PPIs in cultured cells is crucial for many fields of biological research. One proven approach is the use of synthetic bivalent chemical ligands to selectively recruit protein domains with engineered mutations (i.e., "bump-and-hole"). Developing new PPI chemical inducers with unique protein domains enables multiplexing and potentially expands the breadth of recruitable proteins. Herein, we describe the design and characterization of a BromoTag- and dTAG-based toolkit to induce protein homo- and heterodimerization. Using a NanoBiT split-luciferase assay, we characterized a library of BromoTag-based homo- (BromoTag/BromoTag) and heterobivalent (BromoTag/dTAG) compounds for their ability to induce neo-PPIs. Compounds were evaluated for activity across multiple cellular applications, including caspase-9 and c-Kit tyrosine kinase activation, with comparable activity to other dimerizer systems. This BromoTag-based protein dimerization toolkit provides a useful alternative to current controlled dimerization systems that will enable robust prototyping of chemically induced proximity.
- Open Access
- 2 July 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (7) , 1672-1686
Mutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.
The β-catenin destruction complex (BDC) regulates WNT-β-catenin signaling and is a prime therapeutic target in colorectal cancer, yet its biochemical complexity has hindered mechanistic understanding. We mapped the sequence-function landscape of the BDC using tiled base editor screens across its components CTNNB1, AXIN1, APC and GSK3B. Amongst ~150 previously unreported mutations that affected WNT signaling, we discovered gain-of-function and separation-of-function alleles that reveal mechanisms of complex assembly, including a β-catenin region regulating TCF/LEF transcription factor binding. Critically, we found that the AXIN1-β-catenin interface controls signaling flux through the oncogenic BDC found in APC-mutant cancers. In cells expressing truncated APC, β-catenin itself scaffolds BDC assembly, establishing a substrate-assisted autoregulatory mechanism. This architecture represents an unexploited therapeutic vulnerability: strengthening the AXIN1-β-catenin interaction restores destruction complex function and impairs the growth of colorectal cancer cells. Our mutational resource provides a foundation for mechanistic understanding and therapeutic targeting of the WNT pathway.
- 2 July 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (7) , 1672-1686
Open AccessMutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.
The β-catenin destruction complex (BDC) regulates WNT-β-catenin signaling and is a prime therapeutic target in colorectal cancer, yet its biochemical complexity has hindered mechanistic understanding. We mapped the sequence-function landscape of the BDC using tiled base editor screens across its components CTNNB1, AXIN1, APC and GSK3B. Amongst ~150 previously unreported mutations that affected WNT signaling, we discovered gain-of-function and separation-of-function alleles that reveal mechanisms of complex assembly, including a β-catenin region regulating TCF/LEF transcription factor binding. Critically, we found that the AXIN1-β-catenin interface controls signaling flux through the oncogenic BDC found in APC-mutant cancers. In cells expressing truncated APC, β-catenin itself scaffolds BDC assembly, establishing a substrate-assisted autoregulatory mechanism. This architecture represents an unexploited therapeutic vulnerability: strengthening the AXIN1-β-catenin interaction restores destruction complex function and impairs the growth of colorectal cancer cells. Our mutational resource provides a foundation for mechanistic understanding and therapeutic targeting of the WNT pathway.
- Open Access
- 27 May 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (6) , 799-809.e10
The molecular basis for nuclear pore destruction by a proximity-inducing molecular glue
- 27 May 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (6) , 799-809.e10
Open AccessThe molecular basis for nuclear pore destruction by a proximity-inducing molecular glue
- 1 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 670-676
Insights on Future Directions in Cancer Research from the 2026 AACR NextGen Stars
- 1 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 670-676
Insights on Future Directions in Cancer Research from the 2026 AACR NextGen Stars
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.